Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

200961 citationsJournal Article

Authors

Gennady Landa · New York Eye and Ear Infirmary

Wendewessen Amde · New York Eye and Ear Infirmary

Vatsal Doshi · New York Eye and Ear Infirmary

Amro Ali · New York Eye and Ear Infirmary

Laura McGevna · University of Vermont

Ronald C. Gentile · New York Eye and Ear Infirmary

Thomas O. Muldoon

Abstract

Bevacizumab and ranibizumab treatments resulted in similar gains in visual acuity and reduction in macular thickness, documented each month following injection. Intravitreal bevacizumab appears to be as safe and effective as intravitreal ranibizumab in the treatment of exudative AMD.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Ophthalmologica

Volume 223, Issue 6, pp. 370-375

DOI: 10.1159/000227783

Field-Weighted Citation Impact: 10.76

Command Palette